Skip to content

International HIV Antiretroviral Adherence, Resistance and Survival

Novel Approaches to Monitoring and Utilizing Adherence to HIV Therapy in Uganda

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01596322
Acronym
UARTO
Enrollment
750
Registered
2012-05-11
Start date
2004-09-30
Completion date
2015-09-30
Last updated
2017-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Keywords

HIV/AIDS in resource limited setting, HIV treatment outcomes in resource limited setting, Adherence to HIV treatment in resource limited setting, ART resistance in resource limited setting

Brief summary

Real-time Wireless Adherence Monitoring to HIV Antiretroviral Therapy in Rural Uganda.

Detailed description

The investigators will study use a novel method of real-time wireless adherence monitoring in one of the best established multi-disciplinary HIV antiretroviral treatment cohorts in rural Africa. The investigators will advance our theoretical understanding of HIV antiretroviral adherence behavior, HIV pathogenesis, and to address the monitoring and prevention of HIV antiretroviral treatment failure. Based on a successful pilot study in rural Uganda and favorable cost-effective estimates, the investigators will deploy the Wisepill real-time wireless adherence monitoring system to objectively monitor adherence in real time. The investigators will determine to what extent social capital mitigates economic barriers to long-term adherence and determine if the pervasive impact of stigma on adherence operates through social capital (Aim 1). The investigators will determine the relationship between missed doses, low-level viremia (between 1 and 50 copies RNA/mL), inflammation, bacterial translocation, suboptimal CD4 response, and mortality (Aim 2). Finally, The investigators will examine the relationship between complex adherence patterns and viral failure to both inform selective viral load monitoring and to lay the foundation for the first-of-kind intervention to prevent viral failure after missed doses, but before viral rebound (Aim 3). The investigators will secure behavioral and biologic data over nine years of potential treatment by recruiting 500 additional people to our existing cohort in Mbarara, Uganda for a total of 750 participants.

Interventions

None listed

Sponsors

University of California, San Francisco
CollaboratorOTHER
Department of Health and Human Services
CollaboratorFED
Mbarara University of Science and Technology
CollaboratorOTHER
University of British Columbia
CollaboratorOTHER
Dana-Farber Cancer Institute
CollaboratorOTHER
Massachusetts General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV positive patients over 18 years * ART naive and initiating therapy at the Mbarara Immune Suppression Syndrome (ISS) Clinic * Live within 60 kilometers of the clinic * Women who have received a single dose of nevirapine for prevention of mother to child transmission, but have not received other ART, will be included

Exclusion criteria

* Patients who do initiate therapy during the course of the study recruitment * Patients who decline or are unable to give consent

Design outcomes

Primary

MeasureTime frameDescription
Adherence to antiretroviral therapyreal time (up to 7 years)Adherence is assessed through a medication event monitoring system which records every time the device is opened (e.g. for pill taking). Before June 2012, this data was stored on the device and downloaded monthly. After June 2012, this data is transmitted through cellular networks to a central server in real time.

Secondary

MeasureTime frameDescription
Correlates of adherence to antiretroviral therapyevery four monthsQuestionnaires are administered to participants regarding factors such as depression, stigma, food insecurity, reproductive health, and economic status.
Biological consequences of adherence (or incomplete adherence)every four months and during adherence interruptionsSpecimens are collected for immunologic and genetic testing at baseline and every four months, as well as during interruptions in adherence as detected by the real time adherence monitoring system.
Adherence to antiretroviral therapy by self reportevery four monthsParticipants report their adherence over the previous 3 and 28 days by doses missed and visual analog scale.

Countries

Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026